Originally published as JCO Early Release 10.1200/JCO.2006.06.4451 on May 8 2006

This Article Full Text Full Text (PDF) Journal of Oncology Practice Summary Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, T. J. Articles by Wolff, A. C. Search for Related Content PubMed PubMed Citation Articles by Smith, T. J. Articles by Wolff, A. C. Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

Thomas J. Smith, (Chair), James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak, Antonio C. Wolff

From the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke Street, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

PURPOSE: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF).

UPDATE METHODOLOGY: The Update Committee completed a review and analysis of pertinent data published from 1999 through September 2005. Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness.

RECOMMENDATIONS: The 2005 Update Committee agreed unanimously that reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20% and no other equally effective regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of FN in patients who are at high risk based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. CSF use allows a modest to moderate increase in dose-density and/or dose-intensity of chemotherapy regimens. Dose-dense regimens should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Prophylactic CSF for patients with diffuse aggressive lymphoma aged 65 years and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections. Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective?
  Jared R. Adams, Cara Angelotta, and Charles L. Bennett
  JCO 2006 24: 2975-2977 [Full Text]

Related Correspondence

• Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
  Gianluigi Ferretti and Paola Papaldo
  JCO 2006 24: 5615-5616 [Full Text]

This article has been cited by other articles:

				N. M. A. Blijlevens, R. M. Logan, and M. G. Netea Mucositis: from febrile neutropenia to febrile mucositis J. Antimicrob. Chemother., May 1, 2009; 63(suppl_1): i36 - i40. [Abstract] [Full Text] [PDF]

				D. A. Yardley Proactive Management of Adverse Events Maintains the Clinical Benefit of Ixabepilone Oncologist, May 1, 2009; 14(5): 448 - 455. [Abstract] [Full Text] [PDF]

				J. Crawford, C. Caserta, F. Roila, and On behalf of the ESMO Guidelines Working Group Hematopoietic growth factors: ESMO Recommendations for the applications Ann. Onc., May 1, 2009; 20(suppl_4): iv162 - iv165. [Full Text] [PDF]

				B. H. Segal Aspergillosis N. Engl. J. Med., April 30, 2009; 360(18): 1870 - 1884. [Full Text] [PDF]

				S. Dumitra, L. Sideris, Y. Leclerc, G. Leblanc, and P. Dube Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy Ann. Onc., April 1, 2009; 20(4): 795 - 796. [Full Text] [PDF]

				M. Moreau, J. Klastersky, A. Schwarzbold, F. Muanza, A. Georgala, M. Aoun, A. Loizidou, M. Barette, S. Costantini, M. Delmelle, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies Ann. Onc., March 1, 2009; 20(3): 513 - 519. [Abstract] [Full Text] [PDF]

				S. S Shord, L. R Bressler, L. Radhakrishnan, N. Chen, and J L. Villano Evaluation of the Modified Diet in Renal Disease Equation for Calculation of Carboplatin Dose Ann. Pharmacother., February 1, 2009; 43(2): 235 - 241. [Abstract] [Full Text] [PDF]

				P. Jenkins and S. Freeman Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer Ann. Onc., January 1, 2009; 20(1): 34 - 40. [Abstract] [Full Text] [PDF]

				P. D. Cole and H. M. Adam Hematopoietic Growth Factors in Pediatric Patients Pediatr. Rev., January 1, 2009; 30(1): 30 - 31. [Full Text] [PDF]

				E. Shochat and V. Rom-Kedar Novel Strategies for Granulocyte Colony-Stimulating Factor Treatment of Severe Prolonged Neutropenia Suggested by Mathematical Modeling Clin. Cancer Res., October 15, 2008; 14(20): 6354 - 6363. [Abstract] [Full Text] [PDF]

				H. W Tuffaha, I. M Treish, and L. Zaru The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 131 - 138. [Abstract] [PDF]

				E. J. Ip, A. Lee-Ma, L. S. Troxell, and J. Chan Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1552 - 1555. [Abstract] [Full Text] [PDF]

				N Walji, A K Chan, and D R Peake Common acute oncological emergencies: diagnosis, investigation and management Postgrad. Med. J., August 1, 2008; 84(994): 418 - 427. [Abstract] [Full Text] [PDF]

				R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia Clin. Cancer Res., June 15, 2008; 14(12): 3889 - 3895. [Abstract] [Full Text] [PDF]

				S. E. Harrington and T. J. Smith The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?" JAMA, June 11, 2008; 299(22): 2667 - 2678. [Abstract] [Full Text] [PDF]

				S. Y. Barbour Caring for the treatment-experienced breast cancer patient: The pharmacist's role Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S16 - S22. [Abstract] [Full Text] [PDF]

				G. H. Lyman Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern J. Oncol. Pract, May 1, 2008; 4(3): 114 - 115. [Full Text] [PDF]

				D. Weycker, J. Malin, J. Edelsberg, A. Glass, M. Gokhale, and G. Oster Cost of neutropenic complications of chemotherapy Ann. Onc., March 1, 2008; 19(3): 454 - 460. [Abstract] [Full Text] [PDF]

				G. von Minckwitz, S. Kummel, A. du Bois, W. Eiermann, H. Eidtmann, B. Gerber, J. Hilfrich, J. Huober, S. D. Costa, C. Jackisch, et al. Pegfilgrastim {+/-} ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study Ann. Onc., February 1, 2008; 19(2): 292 - 298. [Abstract] [Full Text] [PDF]

				J. N.H. Timmer-Bonte, E. M.M. Adang, E. Termeer, J. L. Severens, and V. C.G. Tjan-Heijnen Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy J. Clin. Oncol., January 10, 2008; 26(2): 290 - 296. [Abstract] [Full Text] [PDF]

				H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling In Reply Oncologist, December 1, 2007; 12(12): 1465 - 1466. [Full Text] [PDF]

				J.-J. Lee, M. S. Lam, and A. Rosenberg Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation Ann. Pharmacother., October 1, 2007; 41(10): 1648 - 1659. [Abstract] [Full Text] [PDF]

				B. H. Segal Role of Macrophages in Host Defense Against Aspergillosis and Strategies for Immune Augmentation Oncologist, October 1, 2007; 12(suppl_2): 7 - 13. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				K. A Mergenhagen and M. T Pasko Daptomycin Use After Vancomycin-Induced Neutropenia in a Patient with Left-Sided Endocarditis Ann. Pharmacother., September 1, 2007; 41(9): 1531 - 1535. [Abstract] [Full Text] [PDF]

				D. M. Courtney, A. Z. Aldeen, S. M. Gorman, J. A. Handler, S. M. Trifilio, J. P. Parada, P. R. Yarnold, and C. L. Bennett Cancer-Associated Neutropenic Fever: Clinical Outcome and Economic Costs of Emergency Department Care Oncologist, August 1, 2007; 12(8): 1019 - 1026. [Abstract] [Full Text] [PDF]

				N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167. [Abstract] [Full Text] [PDF]

				J. A. Ajani In Reply J. Clin. Oncol., June 10, 2007; 25(17): 2491 - 2493. [Full Text] [PDF]

				S. M. Lichtman, L. Balducci, and M. Aapro Geriatric Oncology: A Field Coming of Age J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823. [Full Text] [PDF]

				S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]

				A. C. Hirbe, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, K. Trinkaus, A. Apicelli, and K. Weilbaecher Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner Blood, April 15, 2007; 109(8): 3424 - 3431. [Abstract] [Full Text] [PDF]

				H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use Oncologist, April 1, 2007; 12(4): 484 - 494. [Abstract] [Full Text] [PDF]

				G. Ferretti and P. Papaldo Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide? J. Clin. Oncol., December 10, 2006; 24(35): 5615 - 5616. [Full Text] [PDF]

				A. Dekker, S. Bulley, J. Beyene, L. L. Dupuis, J. J. Doyle, and L. Sung Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation J. Clin. Oncol., November 20, 2006; 24(33): 5207 - 5215. [Abstract] [Full Text] [PDF]

				P. S. Hupperets and V. C. Tjan-Heijnen Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer? Ann. Onc., August 1, 2006; 17(8): 1181 - 1183. [Full Text] [PDF]

				J. R. Adams, C. Angelotta, and C. L. Bennett When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective? J. Clin. Oncol., July 1, 2006; 24(19): 2975 - 2977. [Full Text] [PDF]